精神分裂症患者从口服利培酮换用PP1M一年期疗效观察  

A one-year observation of the effect of oral risperidone on schizophrenia patients switching to PP1M

作　　者：班春霞[1] 李冠军[2] 孙仲礼 李广伟[1] 李相 陆敏[1] BAN Chunxia;LI Guanjun;SUN Zhongli(Shanghai Jiading District Mental Health Center,Shanghai 201806,China)

机构地区：[1]上海市嘉定区精神卫生中心,上海201806 [2]上海市精神卫生中心

出　　处：《国际精神病学杂志》2024年第6期1752-1755,1780,共5页Journal Of International Psychiatry

基　　金：上海市嘉定区卫生健康委员会科研课题计划(编号:2021-KY-13)。

摘　　要：目的 评估精神分裂症患者从口服利培酮换用棕榈酸帕利哌酮注射液1个月剂型(oncemonthly paliperidone palmitate,PP1M)1年期的治疗效果。方法 将80例口服利培酮治疗有效的精神分裂症患者随机分为研究组(针剂组)和对照组(口服药物组)各40例,于基线和治疗12个月时分别对两组患者进行阳性及阴性症状量表(PANSS)、个体和社会功能量表(PSP)、药物治疗依从性简明评定量表(BEMIB)评估,并收集相关药物不良反应。结果 两组间PANSS总分及各分量表评分在治疗前后均无明显差异(P>0.05),治疗后,组内比较,PANSS总分及各分量表评分均明显低于治疗前,差异均具有统计学意义(P<0.05);两组PSP评分在基线无明显差异(P>0.05),治疗后,两组PSP评分均有所升高,在“对社会有益的活动”“扰乱及攻击行为”及PSP总分上,研究组分数明显高于对照组,差异具有统计学意义(P<0.05);两组BEMIB评分在基线无明显差异(P>0.05),治疗后,研究组BEMIB评分明显高于对照组,差异具有统计学意义(P<0.05);两组药物不良反应发生率分别为52.6%和40.0%,差异无统计学意义(P>0.05)。结论 在精神分裂症治疗中,PP1M作为口服利培酮的替代药物,可以有效控制患者的临床症状、更好地改善其社会功能及服药依从性,且药物不良反应与口服药物相当,值得在临床上进行推广。Objective Evaluate the treatment effect of oral risperidone switching to once-monthly paliperidone palmitate(PP1M)for a 1-year period in patients with schizophrenia.Methods Eighty patients with schizophrenia who responded well to oral risperidone were randomly divided into two groups(injection group and oral drug group),with 40cases in each group.At baseline and after 12 months of treatment,PANSS,PSP,and BEMIB were used to assess the patients in both groups,and relevant adverse drug reactions were collected.Results There were no significant differences in the total PANSS scores and subscale scores between the two groups before and after treatment(P>0.05).After treatment,the PANSS total scores and subscale scores within the group were significantly lower than before treatment,with statistical significance(P<0.05).There were no significant differences in the PSP scores between the two groups at baseline(P>0.05).After treatment,the PSP scores of both groups increased.In terms of "beneficial activities for society","disruption and aggressive behavior",and the total PSP score,the study group scores were significantly higher than the control group,with statistical significance(P<0.05).There were no significant differences in the BEMIB scores between the two groups at baseline(P>0.05).After treatment,the BEMIB score of the study group was significantly higher than that of the control group,with statistical significance(P<0.05).The incidence of adverse drug reactions in the two groups was 52.6% and 40.0%,respectively,with no significant differences(P>0.05).Conclusions In the treatment of schizophrenia,PP1M can be used as an alternative to oral risperidone,effectively controlling patients' clinical symptoms,better improving their social function and medication adherence,and having drug adverse reactions that are similar to those of oral drugs.It is worth promoting in clinical practice.

关 键 词：精神分裂症 口服利培酮 棕榈酸帕利哌酮注射液(1个月剂型) 疗效 

分 类 号：R749.33[医药卫生—神经病学与精神病学]